Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

The developer of Wegovy will pay Septerna some $200 million in upfront and near-term fees to collaborate on small molecule medicines for weight loss. Novo is racing against rival Eli Lilly to develop ...

Investing.com -- Shares of Septerna, Inc. (Nasdaq:SEPN) surged 60% following the announcement of an exclusive global collaboration and license agreement with Novo Nordisk (NYSE:NVO) to develop oral ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

The $2.2 billion deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and ...